Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20333692 | 0.80 | LTA4H (0.45) | LTA4HHDAC1HDAC2HDAC3PPARG | |
| SCHEMBL20347169 | 0.79 | CYP17A1 (0.43) | CYP17A1 | |
| SCHEMBL20347168 | 0.78 | MEN1 (0.56) | — | |
| SCHEMBL20347171 | 0.78 | ALDH1A1 (0.41) | PPARGPPARAFFAR1 | |
| SCHEMBL20347166 | 0.78 | RARB (0.48) | — | |
| SCHEMBL20347187 | 0.77 | LMNA (0.44) | PPARGPPARA | |
| SCHEMBL20347182 | 0.76 | BRS3 (0.41) | PPARGPPARA | |
| SCHEMBL20347149 | 0.76 | ALDH1A1 (0.43) | PPARGPPARA | |
| SCHEMBL20347179 | 0.75 | BRS3 (0.46) | PPARGFFAR1 | |
| SCHEMBL20347170 | 0.75 | LTB4R2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | LTA4H 217/4885HDAC1 3062/4885HDAC2 2113/4885 |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | LTA4H 217/4885HDAC1 3062/4885HDAC2 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.